The CVS CostVantage model is designed to provide clearer pricing by factoring in the underlying cost of a drug, a defined markup and a dispensing fee that reflects the value of the pharmacy services provided, according to a Jan. 6 news release shared with Becker’s. The approach aims to reduce reliance on cross-subsidization and help address the financial challenges community pharmacies face.
The model is also intended to bring more transparency to the relationship between pharmacies, pharmacy benefit managers and payors, while also improving reimbursement for pharmacies.
This move follows a trend in the industry toward more straightforward drug pricing. For example, Mark Cuban’s online pharmacy, Express Scripts, and CVS are working to make drug pricing more transparent. CVS’ PBM is also set to launch TrueCost in 2025, a program that aims to enhance transparency around administrative fees and prescription drug costs.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.